Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

8301	Companies
115073	Keywords
55420	Articles
62512	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 09/11/2024 at 15:00, 2 months 10 days ago

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Xenetic Biosciences presented at H.C. Wainwright 26th Annual Global Investment Conference. The biopharmaceutical company focuses on immune-oncology technologies for hard-to-treat cancers

Xenetic Biosciences Biopharmaceutical Immune-oncology JTC Team Cancers
BRIEF

published on 08/14/2024 at 14:05, 3 months 7 days ago

Xenetic Biosciences, Inc. publie ses résultats financiers du deuxième trimestre 2024 et fournit une mise à jour de ses activités

Résultats Financiers Biopharmaceutique Développement Clinique Programme D'oncologie Xénétique
BRIEF

published on 08/14/2024 at 14:05, 3 months 7 days ago

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Financial Results Clinical Development Biopharmaceutical Oncology Program Xenetic
PRESS RELEASE

published on 08/14/2024 at 14:00, 3 months 7 days ago

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. reports financial results for Q2 2024, focusing on DNase-based oncology program in preclinical studies with data due before year end. Ended quarter with $7.3M cash

Financial Results Xenetic Biosciences Cash Balance DNase-based Oncology Program Preclinical Studies
BRIEF

published on 05/22/2024 at 23:05, 5 months 29 days ago

Xenetic Biosciences, Inc. Announces Executive Leadership Transition

Xenetic Biosciences Oncology Clinical Development Executive Leadership James Parslow
BRIEF

published on 05/22/2024 at 23:05, 5 months 29 days ago

Xenetic Biosciences, Inc. annonce une transition de direction

Développement Clinique Oncologie Leadership Executif Biosciences Xénétiques James Parslow
PRESS RELEASE

published on 05/22/2024 at 23:00, 5 months 29 days ago

Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Xenetic Biosciences appoints James F. Parslow as interim CEO. The company focuses on innovative immune-oncology technologies for hard-to-treat cancers

Xenetic Biosciences Clinical Development Pancreatic Carcinoma James Parslow Immune-oncology Technologies
BRIEF

published on 05/10/2024 at 14:35, 6 months 11 days ago

Xenetic Biosciences publie ses résultats financiers et ses progrès commerciaux pour le premier trimestre 2024

Résultats Financiers Biosciences Xénétiques Programme D'oncologie Thérapie Basée Sur La DNase Etudes Précliniques
BRIEF

published on 05/10/2024 at 14:35, 6 months 11 days ago

Xenetic Biosciences Reports Q1 2024 Financial Results and Business Progress

Financial Results Xenetic Biosciences Oncology Program DNase-based Therapy Preclinical Studies
PRESS RELEASE

published on 05/10/2024 at 14:30, 6 months 11 days ago

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. reports financial results for Q1 2024 and progress on DNase-based oncology program, including ongoing preclinical studies and funds of $7.8 million

Financial Results Xenetic Biosciences DNase-based Oncology Program Preclinical Studies Cash Reserves

Accesswire

Published on 11/21/2024 at 17:35, 28 minutes ago

1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Published on 11/21/2024 at 17:30, 33 minutes ago

SimpliGov and Proof Partner to Offer Online Notarization
Published on 11/21/2024 at 16:30, 1 hour 33 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 2 hours 2 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 2 hours 3 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 17:58, 4 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 11 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 11 minutes ago

LIGHTON annonce le vif succès de son introduction en Bourse sur Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 12 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 17:51, 12 minutes ago

2CRSi SA: 2CRSi fournit à Exaion, filiale du groupe EDF, des serveurs à hautes performances en immersion en Amérique du Nord

Les Echos

Published on 11/21/2024 at 06:58, 11 hours 5 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 11 hours 5 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 11 hours 5 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 21 hours 56 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 22 hours 43 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE